Kezar Life Sciences, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Kezar Life Sciences announced the completion of its merger with Aurinia Pharma U.S., Inc., resulting in the cancellation of all outstanding common stock, with Tang Capital entities reporting no beneficial ownership post-merger.
NASDAQ
Tang Capital Management and related entities have agreed to tender their 9.0% stake in Kezar Life Sciences in support of the merger with Aurinia Pharmaceuticals, rescinding a prior acquisition proposal.
NASDAQ
SCHEDULE 13D/A: Kezar Life Sciences Shareholder Equal Talent Investments Reports Director Change in Latest SEC Filing
Equal Talent Investments Limited, a significant shareholder in Kezar Life Sciences, Inc., has filed an amended Schedule 13D to report a change in its sole director, with Tracy Gia Yunn Tsoi replacing Suk Ying Pauli Ng.
NASDAQ
SCHEDULE 13D/A: Major Investors Significantly Reduce Stake in Kezar Life Sciences Following Stock Split
Morningside Venture Investments Limited and Equal Talent Investments Limited have significantly reduced their beneficial ownership in Kezar Life Sciences, Inc. through recent stock sales.